CoChat

ALK1 as an emerging target for antiangiogenic therapy of cancer.

Open access

The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.

Abstract

Members of the TGF-β family act on many, if not all, cell types within the body, producing diverse and complex cellular outcomes. Activation of the endothelial cell-restricted TGF-β type I receptor ALK1 results from the binding of several different ligands of the TGF-β family, including bone morphogenetic protein (BMP) 9, BMP10, and TGF-β. Mounting genetic, pharmacologic, and histopathologic evidence supports a critical role for ALK1 signaling in regulation of both developmental and pathologic blood vessel formation. However, the precise function of TGF-β family signaling in endothelial cells is difficult to predict and appears highly context dependent because of the multitude of ligands and receptors influencing the final outcome. Pharmacologic inhibitors of ALK1 have recently been developed and will allow for more accurate studies of ALK1 function in vivo, as well as for assessment of ALK1 as a target for suppression of angiogenesis during tumor development. Herein, we will summarize the current view of ALK1 regulation of endothelial cell phenotype in vitro and in vivo as well as provide an outlook for the ongoing clinical trials of ALK1 inhibitors in malignant disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-01-330142

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Cited by

See all 208

Metadata

Authors
Cunha, S. I., & Pietras, K.
Affiliations
Karolinska Institutet (SE)
Venue
Blood
Published
2011-06-30
Volume
117
Issue
26
Pages
6999-7006
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2078139160
Cited by
184
References
90
Citations by year
2026: 2 · 2025: 2 · 2024: 18 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 16 · 2017: 17 · 2016: 12 · 2015: 16 · 2014: 10 · 2013: 26 · 2012: 10
FWCI
1.45
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ludwig Institute for Cancer Research
  • Acceleron
  • Cancerfonden
  • Karolinska Institutet
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
Keywords
ALK1, TGF-beta type I receptor, anti-angiogenic therapy, tumor angiogenesis, BMP9, BMP10, TGF-beta signaling, endothelial cells, tumor vascularization
MeSH terms
Animals, Humans, Ligands, Neoplasm Proteins, Neoplasms, Signal Transduction, Angiogenesis Inhibitors, Activin Receptors, Type II, Endothelial Cells, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ALK1 as an emerging target for antiangiogenic therapy of cancer. https://app.cochat.ai/papers/10.1182/blood-2011-01-330142
The paper
Cunha, S. I., & Pietras, K. (2011). ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. https://doi.org/10.1182/blood-2011-01-330142

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.